)
NovoCure (NVCR) investor relations material
NovoCure Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Board unanimously recommends approval of Proposal 4 to amend and restate the 2024 Omnibus Incentive Plan, increasing the share reserve by 9 million shares for an estimated two-year runway.
Proposal aims to secure mission-critical talent to advance Tumor Treating Fields (TTFields) technology and maintain a culture of broad-based employee ownership.
Strategic priorities include driving adoption in approved indications, scaling through new launches, advancing innovation, and pursuing profitability.
Voting matters and shareholder proposals
Shareholders are asked to approve the addition of 9 million shares to the 2024 Omnibus Incentive Plan.
Board recommends a vote "FOR" Proposal 4, citing the need for continued capacity to support compensation programs and mission objectives.
Previous shareholder approvals: 84.8% supported a similar share increase in 2024; Say-on-Pay proposals received 97.5% and 98.2% support in 2025 and 2024, respectively.
Board of directors and corporate governance
Compensation Committee, composed solely of independent directors, administers the amended plan.
Governance enhancements include minimum vesting requirements, a fixed share pool with no evergreen provision, and prohibition of liberal share recycling.
- Q1 2026 revenue up 12% to $174.1M; net loss $71.1M; guidance raised for full year.NVCR
Q1 202611 May 2026 - TTFields devices drive growth with new indications, strong data, and global expansion plans.NVCR
Corporate presentation30 Apr 2026 - Shareholders will vote on directors, auditor, executive pay, and a major equity plan amendment.NVCR
Proxy filing20 Apr 2026 - Annual meeting seeks approval for directors, auditor, compensation, and incentive plan.NVCR
Proxy filing20 Apr 2026 - Record 2025 revenues and FDA approval for Optune Pax set the stage for 2026 growth.NVCR
Q4 20258 Apr 2026 - Disciplined focus on GBM and pancreatic cancer aims to drive growth and profitability.NVCR
Leerink Global Healthcare Conference 202610 Mar 2026 - Expanding TTFields therapy targets four solid tumors, driving growth and diversification by 2026.NVCR
Jefferies London Healthcare Conference 20253 Feb 2026 - Q2 2024 revenue up 19% to $150.4M, with positive METIS trial and EBITDA turning positive.NVCR
Q2 20243 Feb 2026 - Major oncology launches and leadership transition position the company for multi-indication growth.NVCR
2024 Wells Fargo Healthcare Conference22 Jan 2026
Next NovoCure earnings date
Next NovoCure earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage